SUMMARY Left ventricular mass, fractional shortening, and end systolic wall stress (mechanical indices) measured by echocardiography and the response of fractional shortening and end systolic wall stress to the infusion of isoproterenol (0-02 yg/kg/min for 5 min) (a non-mechanical index) were studied in 57 patients (mean (SD) age 49(8)) with essential hypertension. Nineteen patients had subnormal end systolic wall stress (group 1), 25 patients had normal end systolic wall stress and slightly increased left ventricular mass (group 2A), and 13 patients had normal end systolic wall stress and considerably increased left ventricular mass (group 2B). Plasma noradrenaline concentration was higher in group 2B than in the other groups. When end systolic wall stress was > 12 g/cm2 this variable showed a significant inverse linear relation with fractional shortening before isoproterenol infusion. The inotropic response to isoproterenol was measured as the increase of fractional shortening corrected for the decrease of end systolic wall stress (A fractional shortening/ -A end systolic wall stress). The mean (SD) change in A fractional shortening/ -A end systolic wall stress was significantly larger in group 1 (1 -40 (0-60) cm2/g) than in group 2A (0-85 (0-39) cm2/g), and was significantly larger in group 2A than in group 2B (0 56 (0 15) cm2/g).
Classification of hypertensive hypertrophy after the discontinuation of antihypertensive drugs. Essential hypertension was diagnosed in all 57 patients and all of them had echocardiographic evidence of left ventricular hypertrophy: (a) interventricular septal wall thickness of > 12 mm at end diastole, (b) left ventricular end diastolic posterior wall thickness of > 12 mm, and (c) left ventricular mass greater than 2 SD deviations above the normal mean. To restrict the study to patients with pure hypertrophy we studied only those with a left ventricular end diastolic diameter of < 55 mm (46 men and 11 women aged 43-68). None of these patients had evidence of other heart disease from their cardiovascular history, or from physical examination, electrocardiography, or echocardiography; and they were all in sinus rhythm without signs of heart failure. Because coronary arteriography was not justified in these patients concomitant coronary artery disease had to be excluded on clinical grounds alone. Thus the patients in this study had arterial hypertension without clinically evident coronary artery disease.
The patients consented to the following tests, which were performed before introduction of antihypertensive treatment or four weeks after its discontinuation. Eight (42%) patients in group 1, 1 1 (44%) patients in group 2A, and five (38%) patients in group 2B had been treated with antihypertensive agents more than four weeks before the study. The duration of treatment was [4] [5] [6] [7] [8] (1) (2) (3) (4) (5) years in group 1, 3X7 (217) years in group 2A, and 4-4 (3 3) years in group 2B. In group 1 five (33%) patients had been on a thiazide, five (33%) on ,B blockers, three (17%) on methyldopa, two (1 1 %) on calcium antagonists, and one (6%) on hydralazine; in group 2A eight (38%), seven (33%), two (10%), two (10%), one (5%) had been on the same drugs, and one (5%) had been on captopril; and in group 2B the corresponding figures were three (38%), three (38%), one (13%), and a blocker in one (13% ). Thus The thickness of the interventricular  septum and ventricular posterior wall was measured  at the time of the R wave on the electrocardiogram  (end diastole) , with the ultrasonic beam directed just below the tip of the anterior mitral leaflet on M mode echocardiograms. The left ventricular diameter was measured as the distance between the echoes of the left ventricular posterior wall and of the interventricular septum, just below the tip of the mitral leaflets at the level of the chordae tendineae. The diameter of the left ventricle was measured at end diastole and end systole (when' the endocardial surface of septum was closest to the posterior wall of the left ventricle). All measurements were made with a centimetre scale superimposed on the echocardiogram. Fractional shortening (an index of the ejection phase) was calculated as left ventricular end diastolic diameter minus left ventricular end systolic diameter divided by left ventricular end diastolic diameter, and the result was expressed as a percentage.
Left ventricular mass was calculated by a pathologically validated regression method: 1-04 (left ventricular end diastolic diameter + interventricular septal and posterior wall thicknesses)3-left ventricular end diastolic diameter') - 14.3 The end systolic wall stress was calculated by the equation: (peak arterial pressure) x (left ventricular end systolic diameter)2/4 (left ventricular wall thickness) x (left ventricular end systolic diameter + wall thickness).4 This is an expression of the average meridional wall stress which may be defined as the force per unit area acting at the equatorial plane ofthe ventricle in the direction of the apex-to-base axis. The calculation of end systolic wall stress from these measures has been validated.56 Table 1 shows the normal values ofhaemodynamic variables obtained from 22 healthy subjects in our We studied the effect of isoproterenol by comparing the relation between fractional shortening and end systolic wall stress before and after isoproterenol. End systolic wall stress was reduced by isoproterenol. To increase the accuracy of the regression line of the relation between fractional shortening and end systolic wall stress before isoproterenol we increased the number of measurements for smaller end systolic wall stress before isoproterenol in 10 patients (five of group 1, four of group 2A, and one of group 2B) by slow infusion of a solution of sodium nitroprusside (25 mg/500 ml). Left ventricular dimension and arterial pressure were recorded every 30 s during the infusion, until the peak arterial pressure decreased by 30% of the initial value or the heart rate increased by 10% of the initial value, because chronotropic change may influence the inotropic effect.4 ADRENERGIC RESPONSES Plasma noradrenaline Before the start of echocardiographic examination after isoproterenol infusion we collected venous blood samples to determine plasma noradrenaline. Samples were collected after the subject had rested supine for at least 20 minutes with an indwelling butterfly needle in an arm vein. Plasma was separated in a refrigerated centrifuge at 2°C and stored at -40°C. Noradrenaline was adsorbed on to activated alumina at pH by adding Tris-HCl buffer (pH 8-55). Noradrenaline-adsorbed alumina was washed by water followed by elution with 100 Ml of0-25 mol/l acetic acid. After purification with alumina, noradrenaline was separated by high-performance liquid chromatography and was measured spectrofluorometrically by the trihydroxyindole method (Shimadzu spectrofluorometer RF-500 LCA). (Table 1 shows the normal value.) Sugishita, Iida, Yukisada, Ito Isoproterenol echocardiography The study was performed in the afternoon in all patients. Simultaneous cross sectional and M mode echocardiographic and electrocardiographic baseline recordings and blood pressure measurements were performed with the patient in a supine position immediately before intravenous infusion of isoproterenol (0-02 pg/kg/min) via a calibrated infusion pump. After 5 minutes' infusion, cross sectional and M mode echocardiograms and an electrocardiogram were recorded and blood pressure was measured by cuff sphygmomanometer. The transducer was held at the same part on the chest wall throughout the examinations. To standardise the technique between patients, as well as in the same patient before and after the infusion of isoproterenol, we tried to record the echocardiograms at the same part of the left ventricle (just below the tip of the anterior mitral leaflet) before and after the infusion of isoproterenol. The beams of M mode echocardiography were aligned perpendicularly with the posterior walls of the left ventricle and with the wall of the interventricular septum in all the patients both before and after the infusion of isoproterenol.
STATISTICAL ANALYSIS
We used the t test, paired t test, correlation, regression equations, F test, and one-way analysis of variance as appropriate. All results in which p < 0-05 were regarded as statistically significant. Table 2 shows the values ofhaemodynamic, echocardiographic, and other variables before the infusion of isoproterenol. There were no significant differences in age, sex, and heart rate among the groups. Systolic blood pressure was significantly lower in group 1 than in groups 2A and 2B (p < 0 01 and p < 0-001 respectively). Left ventricular end diastolic and end systolic diameters were significantly smaller in group 1 than in groups 2A and 2B (p < 0 05 and p < 0 05; p < 0-001 and p < 0 001 respectively). Fractional shortening was significantly larger in group 1 than in groups 2A and 2B (p < 0001 and p < 0001 respectively), but there was no significant difference between group 2A and group 2B. The interventricular septum was significantly thicker in groups 1 It has been suggested that, as well as mechanical factors, neurohormonal influences could have an important role in the cardiac hypertrophy of hypertension.'8 Small doses of isoproterenol or other catecholamines produced hypertrophy in laboratory animals without changing blood pressure and heart rate. '9 20 The aetiology of hypertrophic cardiomyopathy is not yet known. A disorder of catecholamine function has been suggested,2' and hypersensitivity of the ,B adrenergic receptor system has been proposed to explain hypertrophic cardiomyopathy with asymmetric septal hypertrophy. 22 Whether the presence of asymmetric septal hypertrophy in hypertensive patients is the result of a strong response to an increased afterload or is a coincidental occurrence is not clear. In our study, asymmetric septal hypertrophy was more common in groups 1 and 2B than in group 2A. It may be that the mechanisms of asymmetric septal hypertrophy differed in groups 1 and 2B. The adrenergic response in group 1 resembled that found in hypertrophic cardiomyopathy, whereas that in group 2B resembled the response to high arterial pressure.
Results

HAEMODYNAMIC AND ECHOCARDIOGRAPHIC FINDINGS
In patients in group 1 end systolic wall stress was less than normal, and these patients were more responsive to isoproterenol than those with the other types of hypertensive hypertrophy. Hypertrophy in group 1 may be the result of a combination of the hypertension and a factor causing hypertrophic cardiomyopathy; this second factor will be difficult to identify since in hypertrophic cardiomyopathy, by definition, there is no cause established. Alternatively, patients in group 1 may have had an early stage of hypertension; this is not likely, however, as these patients were not young and they had had hypertension for at least five years.
Group 2B (severe hypertrophy) was significantly less responsive to isoproterenol than group 2A (mild hypertrophy) (p < 0-01). This clinical result may support the experimental results of others. 23 The blunting of inotropic responsiveness to ,B adrenergic stimulation may be one of the mechanisms causing progression from left ventricular hypertrophy to heart failure in hypertensive disease.
The degree of left ventricular hypertrophy has been reported to be positively related to circulating concentrations of plasma noradrenaline.24 But this relation is still controversial. In our study, increased concentrations of plasma noradrenaline were found only in group 2B. Patients in group 1 had normal plasma noradrenaline. Perhaps the increase in plasma noradrenaline in hypertensive hypertrophy is a secondary phenomenon. A depressed P adrenergic reserve might prompt a compensatory increase in plasma noradrenaline.
CLINICAL IMPLICATIONS
Our study showed that inotropic responsiveness to isoproterenol infusion was higher in hearts with lower than normal values for end systolic wall stress than hearts with other types of hypertensive hypertrophy, although hypertrophy in the former group was not mild. On the other hand, patients with normal end systolic wall stress and severe hypertrophy were less responsive to ,B adrenergic stimulation than those with the other hypertensive hypertrophy. The inotropic responsiveness to isoproterenol might be regulated by the conditions of ,B adrenergic receptors in the myocardium when myocardial contractility is normal. Myocardial contractility did not appear to differ among the three groups-groups 1 and 2 seemed to be on the same regression line in fig 1. Groups 2A and 2B did not show significantly different fractional shortening and end systolic wall stress.
In hypertensive patients with subnormal end systolic wall stress and increased responsiveness to isoproterenol, cardiac hypertrophy (inappropriate hypertrophy) may have been induced by a nonmechanical (probably neurohormonal) factor; but in those with normal end systolic wall stress the cardiac hypertrophy (appropriate hypertrophy) might have been induced by a mechanical factor (for example high arterial pressure) and might progress to left ventricular dysfunction with impairment of /3 adrenergic reserve and increased plasma noradrenaline. Thus classification of hypertensive hypertrophy according to the contribution made by a mechanical factor (left ventricular systolic wall stress) and a non-mechanical factor (,B adrenergic response) may be useful in identifying the aetiology and pathophysiology in individual patients.
